Breaking News, Collaborations & Alliances

GSK and CureVac Restructure Collaboration

Will apply GSK's capabilities, partnerships and intellectual property to CureVac's technology to deliver vaccines.

Author Image

By: Charlie Sternberg

Associate Editor

GSK plc and CureVac N.V. have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities. Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. All candidat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters